Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

Silvio Danese, Antonio Gasbarrini

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Fingerprint

Entra nei temi di ricerca di 'Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial'. Insieme formano una fingerprint unica.

Pharmacology, Toxicology and Pharmaceutical Science